Dermorphin for Health & Longevity

Created on 10/29/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Dermorphin, a short amino-acid chain from frog skin that acts on the same receptors as morphine, was tested for pain relief and is sold by unregulated vendors. One small, unrepeated surgical trial found an injection into the spinal fluid relieved pain longer than morphine; nothing measured relates to ageing or lifespan. Opioid harms apply: slowed breathing, dependence, hormone suppression; the frog-secretion ritual has caused deaths, mostly not through this peptide. (Full Review)

Protocol

Published spinal regimen
20 µg once, into the spinal fluid
No therapeutic protocol exists. Research regimen given by anaesthetists in hospital; requires a lumbar puncture and monitored recovery. Carries no information about any other route.
Published intravenous research regimen
5.5 µg/kg/min over 30 minutes
Used purely to probe hormone release in volunteers, not as a treatment; a separate study used 0.16 mg/kg intravenously.
Single versus split dosing
One dose
No study has compared divided dosing, and no data support repeated administration.
Time to effect
Pain relief onset (spinal)
First postoperative hours
In surgical patients.
Pain relief duration (spinal)
Beyond 40 hours
Spinal effects far outlast plasma presence.
Ritual-route stamina and mood
Hours to days
After the acute reaction resolves; uncontrolled self-report on the whole secretion, not dermorphin.

Benefits

Contraindications
  • Anyone with sleep-disordered breathing or lung disease, including severe obstructive sleep apnoea (30 or more breathing pauses per hour of sleep) or chronic obstructive pulmonary disease
  • People with current or past opioid use disorder, or receiving opioid agonist treatment
  • Pregnant or breastfeeding women
  • People with cardiac disease, including recent myocardial infarction within 90 days, or uncorrected electrolyte disturbance
  • People with untreated adrenal insufficiency or an untreated pituitary tumour
  • Anyone who cannot be observed by another person with rescue capability during and after exposure
Key Interactions
  • Opioid antagonists (naloxone, naltrexone, nalmefene): loss of effect, incomplete rescue, or precipitated withdrawal
Theoretical (inferred from mechanism)
  • Central nervous system depressants (benzodiazepines like diazepam, Z-drugs, gabapentinoids, alcohol): slowed or stopped breathing
  • Other mu-opioid agonists (morphine, fentanyl, loperamide at high dose): additive respiratory depression and sedation
  • Sedating and serotonergic medications (antidepressants sertraline, amitriptyline and phenelzine, and the antipsychotic quetiapine): excessive sedation and circulatory collapse
  • Drugs lowering the seizure threshold or altering fluid balance (diuretics, desmopressin, carbamazepine): worsened dangerously low blood sodium when combined with induced vomiting and water loading
  • Supplements with sedative or respiratory-depressant activity (kava, valerian, melatonin at high dose, phenibut): deepened sedation
  • Supplements and foods affecting opioid-sensitive gut motility (magnesium, senna): unpredictable constipation or cramping
  • Peptidase-dependent clearance, not cytochrome P450: common cytochrome-based interactions (grapefruit juice, ketoconazole) are not expected to apply

Risk & Side Effects

  • Low: Slowed or stopped breathing; tolerance, physical dependence and withdrawal; suppression and disruption of reproductive, adrenal and thyroid hormones; nausea and vomiting; urinary retention; severe and fatal harm from the traditional frog-secretion route
  • Speculative: Cardiovascular and autonomic disturbance

Monitoring

Marker Target Why
Serum sodium 135–145 mmol/L Safety check; a result below range stops use
Breathing during sleep (overnight oximetry or sleep study) 30 or more breathing pauses per hour marks the group at greatest risk Unwitnessed apnoea is the mechanism of opioid death
Total testosterone (men) 264–916 ng/dL Sustained mu-opioid activity suppresses it
Luteinizing hormone 1.7–8.6 IU/L in men, cycle-dependent in women Separates central from testicular suppression
Prolactin 4–15 ng/mL in men, 4–23 ng/mL in women Persistent rise signals continuing pituitary effect
Morning cortisol 5–25 µg/dL at 8 a.m. Safety check; a low value indicates a blunted stress response
Thyroid-stimulating hormone 0.4–4.0 mIU/L Dermorphin raised it in volunteers
Free thyroxine Not specified in the ER Paired with thyroid-stimulating hormone if out of range

Cadence: Sodium, breathing during sleep and baseline hormones before any exposure. No established cadence for this compound; in class practice, hormones are rechecked after roughly 4 to 8 weeks of repeated exposure and then every 6 to 12 months, and sodium before each ritual-route exposure and whenever vomiting and heavy water intake occur together.

Qualitative Assessment

  • Daytime sleepiness, and any report by a bed partner of pauses in breathing or heavy snoring after exposure
  • Constipation, nausea, or difficulty emptying the bladder
  • Sexual function, morning erections, menstrual regularity, and libido over weeks rather than days
  • Mood, irritability, and any craving or preoccupation with the next exposure
  • Whether the subjective lift reported after ritual use persists beyond the first days, or inverts into fatigue